BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
December 06, 2024 16:35 ET | Source: BioAge Labs, Inc. Decision follows…
Search
Have an existing account?
Sign In
Tag: Nasdaq:BIOA